Proteome Sciences (AIM:PRM) - leading the way in diagnosis and disease monitoring
Increased awareness of the factors associated with disease has been accompanied by research within proteomics. It has been recognised that observing changes in protein markers can be important for both diagnosis and disease monitoring, as well as for the development of novel therapeutics. We’re taking a glance at one pioneer, Proteome Sciences (AIM:PRM), whose work has shown some interesting progressions in recent months.
With a growing demand for personalised medicine, the proteomics market has taken off substantially over the past few years. The work by Proteome Sciences focuses specifically on Biomarkers, Biomarker Assays and Isobaric and Isotopic Reagents, alongside the offering of Biomarker Services. The company have successfully established an IP portfolio of biomarkers associated with a range of diseases, as well as a patented tagging technology ‘Tandem Mass Tag®’ (TMT®), which can assist in the measurement of proteins in biological samples. TMT®, a range of isobaric and isotopic reagents, allows for the tagging of proteins and peptides. The unique process is commercially…